MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00330-026-12922-9

Медицинская библиотека · European radiology · 2026

Preoperative [18F]FAPI-42 PET/CT is associated with tumor budding in colorectal cancer: a dual-center retrospective study.

Mu Xingyu, He Ge, Huang Xiaoqi, Li Jingze, Lu Denglu, Li Zuguo, Fu Wei, Deng Yanyun

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

To determine whether preoperative [18F]FAPI-42 PET/CT is associated with postoperative pathological phenotypes and tumor budding grade in colorectal cancer.

MATERIALS AND

METHODS

This retrospective dual-center study included consecutive adults who underwent [18F]FAPI-42 PET/CT before surgery between January 2022 and January 2026. The index test was quantitative primary-tumor PET uptake; the reference standard was surgical pathology including tumor budding grade. PET parameters were compared across postoperative phenotypes and binary budding groups. Logistic regression, receiver operating characteristic analysis, calibration, bootstrap validation, and decision-curve analysis were performed.

RESULTS

Sixty-four patients (mean age, 63.8 years ± 9.4; 40 men) with 65 primary lesions were analyzed. Maximum standardized uptake value (SUVmax) differed significantly by tumor budding grade among seven phenotypes (p = 0.012). Intermediate/high-grade budding lesions had higher SUVmax than low-grade lesions (12.66 ± 3.36 versus 10.16 ± 3.86; p = 0.012). A model combining body mass index and SUVmax achieved an area under the curve of 0.841 (95% confidence interval: 0.731, 0.934), with an optimism-corrected area under the curve of 0.830.

CONCLUSION

Preoperative [18F]FAPI-42 PET/CT uptake was associated with colorectal cancer tumor budding. A simple body mass index-SUVmax model provides internally validated, interpretable preoperative information on tumor budding grade; however, independent multicenter external validation is required before clinical application.

KEY POINTS: Question Can preoperative fibroblast activation protein inhibitor PET/CT identify colorectal cancer tumor budding, a clinically relevant marker of aggressive invasive-front biology? Findings Higher [18F]FAPI-42 uptake was associated with intermediate/high-grade tumor budding; combining body mass index and maximum standardized uptake value improved discrimination. Clinical relevance Fibroblast activation protein inhibitor PET/CT may support noninvasive preoperative risk stratification of colorectal cancer by identifying tumor budding-related aggressive biology without additional procedures.

Для цитирования: Mu Xingyu, He Ge, Huang Xiaoqi, Li Jingze, Lu Denglu, Li Zuguo, Fu Wei, Deng Yanyun. Preoperative [18F]FAPI-42 PET/CT is associated with tumor budding in colorectal cancer: a dual-center retrospective study.. European radiology. 2026. DOI: 10.1007/s00330-026-12922-9.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.